Literature DB >> 29513072

Regulation of fluid reabsorption in rat or mouse proximal renal tubules by asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase 1.

Tracy Bell1, Magali Araujo2, Zaiming Luo2, James Tomlinson3, James Leiper4, William J Welch2, Christopher S Wilcox2.   

Abstract

Nitric oxide prevents hypertension yet enhances proximal tubule Na+ reabsorption. Nitric oxide synthase is inhibited by asymmetric dimethylarginine (ADMA) that is metabolized by dimethylarginine dimethylaminohydrolase (DDAH) whose type 1 isoform is expressed abundantly in the proximal tubule (PT). We hypothesize that ADMA metabolized by DDAH-1 inhibits fluid reabsorbtion (Jv) by the proximal tubule. S2 segments of the PT were microperfused between blocks in vivo to assess Jv in anesthetized rats. Compared with vehicle, microperfusion of ADMA or Nω-nitro-l-arginine methyl ester (l-NAME) in the proximal tubule reduced Jv dose dependently. At 10-4 mol/l both reduced Jv by ~40% (vehicle: 3.2 ± 0.7 vs. ADMA: 2.1 ± 0.5, P < 0.01 vs. l-NAME: 1.9 ± 0.4 nl·min-1·mm-1, P < 0.01; n = 10). Selective inhibition of DDAH-1 in rats with intravenous L-257 (60 mg/kg) given 2 h before and L-257 (10-5 mol/l) perfused in the proximal tubule for 5 min reduced Jv by 32 ± 4% (vehicle: 3.2 ± 0.5 vs. L-257: 2.2 ± 0.5 nl·min-1·mm-1; P < 0.01) and increased plasma ADMA by ≈50% (vehicle: 0.46 ± 0.03 vs. L-257: 0.67 ± 0.03 µmol/l, P < 0.0001) without changing plasma symmetric dimethylarginine. Compared with nontargeted control small-interference RNA, knock down of DDAH-1 in mice by 60% with targeted small-interference RNAs (siRNA) reduced Jv by 29 ± 5% (nontargeted siRNA: 2.8 ± 0.20 vs. DDAH-1 knockdown: 1.9 ± 0.31 nl·min-1·mm-1, P < 0.05). In conclusion, fluid reabsorption in the proximal tubule is reduced by tubular ADMA or by blocking its metabolism by DDAH-1. L-257 is a novel regulator of proximal tubule fluid reabsorption.

Entities:  

Keywords:  L-257; l-nitromethyl arginine; micropuncture; nitric oxide; proximal tubule

Mesh:

Substances:

Year:  2018        PMID: 29513072      PMCID: PMC6087787          DOI: 10.1152/ajprenal.00560.2017

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  28 in total

1.  Isoform-specific regulation by N(G),N(G)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO.

Authors:  Dan Wang; Pritmohinder S Gill; Tinatin Chabrashvili; Maristela L Onozato; Julie Raggio; Margarida Mendonca; Kathryn Dennehy; Min Li; Paul Modlinger; James Leiper; Patrick Vallance; Oscar Adler; Anna Leone; Akihiro Tojo; William J Welch; Christopher S Wilcox
Journal:  Circ Res       Date:  2007-08-02       Impact factor: 17.367

Review 2.  Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective.

Authors:  C Zoccali
Journal:  Kidney Int       Date:  2006-05-24       Impact factor: 10.612

Review 3.  The biology and therapeutic potential of the DDAH/ADMA pathway.

Authors:  F Arrigoni; B Ahmetaj; J Leiper
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

4.  Acute antihypertensive action of nitroxides in the spontaneously hypertensive rat.

Authors:  Kinjal Patel; Yifan Chen; Kathryn Dennehy; Jonathan Blau; Stephanie Connors; Margarida Mendonca; Margaret Tarpey; Murali Krishna; James B Mitchell; William J Welch; Christopher S Wilcox
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-09-22       Impact factor: 3.619

Review 5.  Dimethylarginines ADMA and SDMA: the real water-soluble small toxins?

Authors:  Eva Schepers; Timo Speer; Stefanie M Bode-Böger; Danilo Fliser; Jan T Kielstein
Journal:  Semin Nephrol       Date:  2014-02-17       Impact factor: 5.299

Review 6.  Nitric oxide synthase derangements and hypertension in kidney disease.

Authors:  Chris Baylis
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-01       Impact factor: 2.894

7.  Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney.

Authors:  A Tojo; W J Welch; V Bremer; M Kimoto; K Kimura; M Omata; T Ogawa; P Vallance; C S Wilcox
Journal:  Kidney Int       Date:  1997-12       Impact factor: 10.612

8.  Dimethylarginine dimethylaminohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt.

Authors:  Ping Zhang; Xinli Hu; Xin Xu; Yingjie Chen; Robert J Bache
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-01-06       Impact factor: 8.311

Review 9.  Regulation of renal NaCl transport by nitric oxide, endothelin, and ATP: clinical implications.

Authors:  Jeffrey L Garvin; Marcela Herrera; Pablo A Ortiz
Journal:  Annu Rev Physiol       Date:  2011       Impact factor: 19.318

10.  Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.

Authors:  James A P Tomlinson; Ben Caplin; Olga Boruc; Claire Bruce-Cobbold; Pedro Cutillas; Dirk Dormann; Peter Faull; Rebecca C Grossman; Sanjay Khadayate; Valeria R Mas; Dorothea D Nitsch; Zhen Wang; Jill T Norman; Christopher S Wilcox; David C Wheeler; James Leiper
Journal:  J Am Soc Nephrol       Date:  2015-04-08       Impact factor: 10.121

View more
  2 in total

1.  DDAH-1, via regulation of ADMA levels, protects against ischemia-induced blood-brain barrier leakage.

Authors:  Yichen Zhao; Xiaoye Ma; Yuchen Zhou; Junchao Xie; Xueyuan Liu; Yanxin Zhao
Journal:  Lab Invest       Date:  2021-02-11       Impact factor: 5.662

2.  Enhancing kidney DDAH-1 expression by adenovirus delivery reduces ADMA and ameliorates diabetic nephropathy.

Authors:  Michael D Wetzel; Ting Gao; Kristen Stanley; Timothy K Cooper; Sidney M Morris; Alaa S Awad
Journal:  Am J Physiol Renal Physiol       Date:  2020-01-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.